3-{3-[3-(2,4-dichlorophenoxy)-2(S)-hydroxypropoxy]phenyl}-2(S)-isopropoxypropanoic acid | 478925-95-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-{3-[3-(2,4-dichlorophenoxy)-2(S)-hydroxypropoxy]phenyl}-2(S)-isopropoxypropanoic acid
• 英文别名: (2S)-3-[3-[(2S)-3-(2,4-dichlorophenoxy)-2-hydroxypropoxy]phenyl]-2-propan-2-yloxypropanoic acid
• CAS: 478925-95-0
• 化学式: C₂₁H₂₄Cl₂O₆
• 分子量: 443.324
• InChiKey: KVMLDUFYRBHZLA-JXFKEZNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-{3-[3-(2,4-dichlorophenoxy)-2(S)-hydroxypropoxy]phenyl}-2(S)-isopropoxypropanoic acid ethyl ester 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 3-{3-[3-(2,4-dichlorophenoxy)-2(S)-hydroxypropoxy]phenyl}-2(S)-isopropoxypropanoic acid
  参考文献：
  名称：

  EP1380562

  摘要：

  公开号：

文献信息

• Carboxylic acid derivative and salt thereof
  申请人：——

  公开号：US20040102634A1

  公开（公告）日：2004-05-27

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. 1 Wherein R 1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C 1-3 alkylene group, a C 2-3 alkenylene group or a C 2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; 2 represents a single bond etc.; X represents a single bond, oxygen atom, a group represented by —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or sulfur atom; and R X1 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents), —OCQ 1 NR X1 — (wherein Q 1 and R X1 are as defined above), —CQ 1 NR X1 O— (wherein Q 1 and R X1 are as defined above), ONR X1 CQ 1 — (wherein Q 1 and R X1 are as defined above), -Q 2 SO 2 — (wherein Q 2 is an oxygen atom or —NR X10 — (wherein R X10 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents)) or —SO 2 Q 2 - (wherein Q 2 is as defined above), (wherein, provided that R X2 and R X3 , and/or R X4 and R X5 may together form a ring, Q 3 and Q 4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NR X10 (wherein NR X10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5- to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

  本发明提供了一种新型的羧酸化合物、其盐或水合物，作为胰岛素增敏剂，并且提供了一种包含该化合物作为活性成分的药物。即，本发明提供了由以下式表示的羧酸化合物、其盐、酯或水合物。其中，R1表示氢原子、羟基、卤素、羧基或C1-6烷基等，每个都可以有一个或多个取代基；L表示单键，或C1-6烷基、C2-6烯基或C2-6炔基等，每个都可以有一个或多个取代基；M表示单键，或C1-6烷基、C2-6烯基或C2-6炔基等，每个都可以有一个或多个取代基；T表示单键，或C1-3烷基、C2-3烯基或C2-3炔基等，每个都可以有一个或多个取代基；W表示羧基；2表示单键等；X表示单键、氧原子、由—NRX1CQ1O—表示的基团（其中，Q1表示氧原子或硫原子；RX1表示氢原子、甲酰基或C1-6烷基等，每个都可以有一个或多个取代基）、由—OCQ1NRX1—表示的基团（其中，Q1和RX1如上所定义）、由—CQ1NRX1O—表示的基团（其中，Q1和RX1如上所定义）、由ONRX1CQ1—表示的基团（其中，Q1和RX1如上所定义）、由-Q2SO2—表示的基团（其中，Q2是氧原子或—NRX10—（其中，RX10表示氢原子、甲酰基或C1-6烷基等，每个都可以有一个或多个取代基））或由—SO2Q2—表示的基团（其中，Q2如上所定义），（其中，假设RX2和RX3，以及RX4和RX5可以共同形成环，Q3和Q4相同或不同，每个表示氧原子、（O）S（O）或NRX10（其中，NRX10如上所定义））；Y表示5-至14-成员芳香基等，可以有一个或多个取代基和一个或多个杂原子；环Z表示5-至14-成员芳香基，可以有0至4个取代基和一个或多个杂原子，其中环的一部分可以饱和。
• CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1380562A1

  公开（公告）日：2004-01-14

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. Wherein R1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C1-3 alkylene group, a C2-3 alkenylene group or a C2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; - - - represents a single bond etc. ; X represents a single bond, oxygen atom, a group represented by -NRX1CQ1O- (wherein Q1 represents an oxygen atom or sulfur atom; and RX1 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents), -OCQ1NRX1- (wherein Q1 and RX1 are as defined above), -CQ1NRx1O- (wherein Q1 and RX1 are as def ined above), ONRX1CQ1- (wherein Q1 and RX1 are as defined above), - Q2SO2- (wherein Q2 is an oxygen atom or -NRX10- (wherein RX10 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents)) or -SO2Q2- (wherein Q2 is as defined above), (wherein, provided that RX2 and RX3, and/or RX4 and RX5 may together form a ring, Q3 and Q4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NRX10 (wherein NRX10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5-to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

  本发明提供了一种可用作胰岛素增敏剂的新型羧酸化合物、其盐或其水合物，以及包含该化合物作为活性成分的药物。也就是说，本发明提供了由下式代表的羧酸化合物、其盐、其酯或它们的水合物。 其中 R1 代表氢原子、羟基、卤素、羧基或 C1-6 烷基等、L 代表单键，或 C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，其中每个基团可带有一个或多个取代基；M 代表单键，或 C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，其中每个基团可有一个或多个取代基； T 代表单键，或 C1-3 亚烷基、C2-3 亚烯基或 C2-3 亚炔基，其中每个基团可有一个或多个取代基； W 代表羧基； - - - 代表单键等；X 代表单键、氧原子、由 -NRX1CQ1O- 代表的基团（其中 Q1 代表氧原子或硫原子；RX1 代表氢原子、甲酰基或 C1-6 烷基等）、其中每个取代基可有一个或多个）、-OCQ1NRX1-（其中 Q1 和 RX1 如上定义）、-CQ1NRx1O-（其中 Q1 和 RX1 如上定义）、ONRX1CQ1-（其中 Q1 和 RX1 如上定义）、-Q2SO2-（其中 Q2 是氧原子或-NRX10-（其中 RX10 代表氢原子、甲酰基或 C1-6 烷基等、其中每个基团可具有一个或多个取代基））或-SO2Q2-（其中 Q2 如上定义）、 (其中，只要 RX2 和 RX3，和/或 RX4 和 RX5 可共同形成一个环，Q3 和 Q4 彼此相同或不同，且各自代表氧原子、（O）S（O）或 NRX10（其中 NRX10 如上定义））；Y 代表 5 至 14 元芳香基团等、环 Z 代表 5 至 14 元芳香基团，可具有 0 至 4 个取代基和一个或多个杂原子，其中部分环可为饱和环。
• CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE
  申请人：Eisai Co., Ltd.

  公开号：EP1607103A1

  公开（公告）日：2005-12-21

  An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonistic activity, wherein the agent is so configured that the compound (a) and the compound (b) are used simultaneously, separately or every scheduled time.

  本发明的目的是提供一种对溃疡性结肠炎或克罗恩病等炎症性肠病有效的药物。一种抗肿瘤坏死因子α抗体、一种神经生理激素和一种抗感染化合物，再加上由至少一种具有 PPARγ 激动活性的化合物组成的活性成分（b），其中制剂的配置使化合物（a）和化合物（b）可同时、分别或每次按计划使用。
• Concomitant drug as therapeutic agent for inflammatory bowel disease
  申请人：Horizoe Tatsuo

  公开号：US20060177444A1

  公开（公告）日：2006-08-10

  An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonistic activity, wherein the agent is so configured that the compound (a) and the compound (b) are used simultaneously, separately or every scheduled time.

  本发明的目的是提供一种对溃疡性结肠炎或克罗恩病等炎症性肠病有效的药物。一种抗肿瘤坏死因子α抗体、一种神经生理激素和一种抗感染化合物，再加上由至少一种具有 PPARγ 激动活性的化合物组成的活性成分（b），其中制剂的配置使化合物（a）和化合物（b）可同时、分别或每次按计划使用。
• US7544835B2
  申请人：——

  公开号：US7544835B2

  公开（公告）日：2009-06-09